|
Osteoporosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lowering SMAD9 as a potential novel anabolic mechanism for osteoporosis therapeutics warrants further investigation.© 2019 The Authors.
|
31525280 |
2020 |
|
Essential Hypertension
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The risk of EH increased in the <i>SMAD9</i> gene rs397514716 locus dominant model (adjusted OR = 1.370, 95% CI: 1.183-1.559, <i>P</i><0.001) and recessive model (adjusted OR = 1.803, 95% CI: 1.470-1.983, <i>P</i><0.001).
|
30617053 |
2019 |
|
Fibrosis, Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ablation of Hepatocyte Smad1, Smad5, and Smad8 Causes Severe Tissue Iron Loading and Liver Fibrosis in Mice.
|
31127639 |
2019 |
|
Iron Overload
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found that Smad8;Alb-Cre<sup>+</sup> mice exhibited no iron phenotype, whereas Smad158;Alb-Cre<sup>+</sup> mice had greater iron overload than Smad15;Alb-Cre<sup>+</sup> mice.
|
31127639 |
2019 |
|
polyps
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
HEK cells transfected to express SMAD9(V90M) had reduced expression of phosphatase and tensin homolog; this reduction was also observed in a polyp from the patient.
|
26122142 |
2015 |
|
Cystic echinococcosis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In the present study, we identified two members of the Smad proteins, Smad8 and Smad4 homologues (termed as EgSmadE and EgSmadD, respectively), from Echinococcus granulosus, the causative agent of cystic echinococcosis (CE).
|
25039015 |
2014 |
|
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
A subset of Smad8 mutants had pulmonary adenomas uncovering a function for Smad8 in normal growth control.
|
19419974 |
2009 |
|
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings implicate Smad8 in both pulmonary hypertension and lung tumorigenesis and support Smad8 as a candidate gene for PAH in humans.
|
19419974 |
2009 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These findings implicate Smad8 in both pulmonary hypertension and lung tumorigenesis and support Smad8 as a candidate gene for PAH in humans.
|
19419974 |
2009 |
|
Associated Pulmonary Arterial Hypertension
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension.
|
19211612 |
2009 |
|
Malignant Neoplasms
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
Elucidation of epigenetic inactivation of SMAD8 in cancer using targeted expressed gene display.
|
14996722 |
2004 |
|
Primary malignant neoplasm
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
Elucidation of epigenetic inactivation of SMAD8 in cancer using targeted expressed gene display.
|
14996722 |
2004 |
|
Benign Prostatic Hyperplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Radical prostatectomy (RP) specimens from 74 patients with clinically localized PC (median follow-up 51 months, range 15-152), 44 benign prostatic hypertrophy (BPH) lesions, and 4 normal prostates (NPs) were assessed for BMP2, Smad8, and Smad4 expression using immunohistochemistry.
|
15042598 |
2004 |
|
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Small hairpin RNA-based gene silencing and gene overexpression approaches reveal that Smads 1 and 5 mediate, whereas Smad8 represses, rapamycin-induced cell death and expression of the bone morphogenetic protein (BMP) transcriptional target Id1 in human prostate cancer cell lines.
|
22452883 |
2012 |
|
Prostate carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Small hairpin RNA-based gene silencing and gene overexpression approaches reveal that Smads 1 and 5 mediate, whereas Smad8 represses, rapamycin-induced cell death and expression of the bone morphogenetic protein (BMP) transcriptional target Id1 in human prostate cancer cell lines.
|
22452883 |
2012 |
|
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that decreased BMP2, nuclear smad8 and nuclear Smad4 expression are associated with the progression to PC, and in particular loss of BMP2 and Smad4 are related to progression to a more aggressive phenotype.
|
15042598 |
2004 |
|
Prostate carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that decreased BMP2, nuclear smad8 and nuclear Smad4 expression are associated with the progression to PC, and in particular loss of BMP2 and Smad4 are related to progression to a more aggressive phenotype.
|
15042598 |
2004 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant neoplasm of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
|
Malignant neoplasm of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
|
Adenoma of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
|
Adenocarcinoma of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
|
Adenocarcinoma of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
|
COLORECTAL CANCER, SUSCEPTIBILITY TO, 1
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
|
COLORECTAL CANCER, SUSCEPTIBILITY TO, 1
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |